Back to Agenda
Impact of COVID-19 on Clinical Trial Execution
Session Chair(s)
Mary Jo Lamberti, PhD, MA
Director of Sponsored Research, Research Associate Professor
Tufts Center for the Study of Drug Development, United States
Senior clinical operations executives at major pharmaceutical and biotech companies within the US shared their insights and lessons learned regarding transition to remote and virtual clinical trials due to COVID-19 through in-depth interviews.
Learning Objective : Describe how COVID-19 has impacted the execution of ongoing clinical trials at pharmaceutical and biotech organizations, including remote and virtual approaches adopted; Discuss how the pandemic will influence clinical trial development in the long-term including increased use of telehealth and other technologies.
Speaker(s)
Supporting Clinical Trial Recruitment During COVID-19
Melanie Goodwin, MS, MSc
Pfizer Inc, United States
Director, Patient Recruitment Programs
Decentralized Trials Scale and Commitment Following the Pandemic
Craig H Lipset, MPH
United States
Managing Partner
Have an account?